论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Zhu Y, Wang XY, Zhang Y, Xu D, Dong J, Zhang Z, Yi CH, Jia HL, Yang X
Received 1 May 2018
Accepted for publication 22 June 2018
Published 2 October 2018 Volume 2018:10 Pages 4113—4123
DOI https://doi.org/10.2147/CMAR.S172719
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Andrew Yee
Peer reviewer comments 2
Editor who approved publication: Professor Nakshatri
Background: Agents targeting the programmed death ligand 1 (PD-L1)/programmed death
receptor 1 immune checkpoint exhibited promising clinical outcomes in a variety
of malignant tumors, including intrahepatic cholangiocarcinoma (ICC). However,
the relationship between PD-L1 expression and CD8+ T-cell immune responses is not well defined in ICC.
Patients and
methods: We investigated PD-L1
expression immunohistochemistry in formalin-fixed, paraffin-embedded tissues
from 192 ICC patients undergoing curative resection and correlated our results
with the clinicopathologic features and prognosis. We also quantified CD8+ T-cell infiltration in ICC specimens and evaluated the
relationship between PD-L1 expression and CD8+ T-cell infiltration. After incubating human ICC cell lines
(HCCC9810 and RBE) with interferon (IFN)-γ, we measured the PD-L1
expression of these ICC cells by Western blot and flow cytometry.
Results: Only 34 patients (17.7%) showed ≥5% membranous PD-L1 expression on
tumor cells, and tumoral PD-L1 overexpression (≥5%) was significantly
associated with superior overall survival (P =0.012) and
disease-free survival (P =0.018). A
significant positive association was found between PD-L1 expression and the
presence of CD8+ T-cells. In fresh
frozen ICC specimens, IFN-γ was found to be significantly correlated with PD-L1
and CD8A gene expression, as evaluated by reverse transcription-polymerase
chain reaction. Moreover, stimulation of the HCCC9810 and RBE cells with
recombinant IFN-γ, secreted by CD8+ T-cells rapidly induced PD-L1 upregulation in these cell lines in
vitro.
Conclusion: Tumor PD-L1 overexpression is mainly stimulated by activated CD8+ T-cells pre-existing in the ICC microenvironment, and PD-L1 is a
favorable prognostic factor for the patients. These observations suggest that
anti-PD-L1/programmed death receptor 1 therapy may benefit ICC patients with
tumor cell PD-L1 expression and the presence of CD8+ T-cells.
Keywords: tumor microenvironment, adaptive immune resistance, PD-L1, CD8+ T-cell, IFN-γ